Braxia Scientific Reports Q3 2024 Financial Results
Toronto, Ontario--(Newsfile Corp. - February 29, 2024) - Braxia Scientific Corp. (CSE: BRAX) (OTC Pink: BRAXF) (FSE: 4960), ("Braxia Scientific", or the "Company"), a medical research company with cli
Braxia Scientific Reports Mandatory Conversion of Debentures
Toronto, Ontario--(Newsfile Corp. - January 15, 2024) - Braxia Scientific Corp. (CSE: BRAX) (OTC Pink: BRAXF) (FSE: 4960), ("Braxia Scientific", or the "Company"), a medical research company with clin
Braxia Scientific Reports Q2 2024 Financial Results and Provides Corporate Update
Toronto, Ontario--(Newsfile Corp. - November 30, 2023) - Braxia Scientific Corp. (CSE: BRAX) (OTC Pink: BRAXF) (FSE: 4960) ("Braxia Scientific", or the "Company"), a medical research company with clin
Braxia Scientific Reports Q1 Fiscal 2024 Financial Results
Toronto, Ontario--(Newsfile Corp. - August 30, 2023) - Braxia Scientific Corp. (CSE: BRAX) (OTC Pink: BRAXF) (FSE: 4960) ("Braxia Scientific", or the "Company"), a medical research and telemedicine co
Braxia Scientific Reports Fiscal 2023 Financial Results
Braxia Health ketamine treatments up 26% YoY in 2023 and revenue up 27% YoYCompany completes dosing of final participant in Phase 2, multi-dose Psilocybin trial, results expected to be published prior
RETRANSMISSION: Braxia Scientific Reports a 26% Increase in Total Treatment Volumes in F2023 and an 87% Increase in Treatments at Newly Expanded Ottawa Clinic
Company Taking Strategic Actions to Prioritize Clinic Expansion, Enhance Operational Effectiveness and Right Size Cost StructureThis release adds information to the press release disseminated on June
Braxia Scientific Reports a 26% Increase in Total Treatment Volumes in F2023 and an 87% Increase in Treatments at Newly Expanded Ottawa Clinic
Company Taking Strategic Actions to Prioritize Clinic Expansion, Enhance Operational Effectiveness and Right Size Cost StructureToronto, Ontario--(Newsfile Corp. - June 9, 2023) - Braxia Scientific Co
Braxia Scientific Provides Update on Proposed Irwin Transaction; Company Retains Strategic Clinical Assets and Ketamine and Psychedelics Clinical IP
Toronto, Ontario--(Newsfile Corp. - March 16, 2023) - Braxia Scientific Corp. (CSE: BRAX) (OTC PINK: BRAXF) (FWB: 4960) ("Braxia", or the "Company"), a medical research and telemedicine company with c
Update on LOI for Business Combination With Braxia Scientific Corp.
LOS ANGELES, March 16, 2023 (GLOBE NEWSWIRE) -- Irwin Naturals Inc. (CSE: IWIN) (OTC: IWINF) (FRA: 97X) ("Irwin" or the "Company"), announced today that it has terminated the non-binding amended and
Express News | Irwin Naturals Brief: Says Has Terminated Non-binding Amended and Restated Letter of Intent for a Business Combination With Braxia Scientific Corp.
SETTLEMENT OF BRAXIA SCIENTIFIC CORP. SECURITIES CLASS ACTION
Braxia Scientific Opens Fifth Clinic in Canada
08:16 AM EDT, 06/15/2022 (MT Newswires) -- Braxia Scientific Corp. (BRAX.CSE), a research company with clinics providing ketamine and psilocybin treatments for depression and related mental health dis
Braxia Scientific Presents Preliminary Findings From Phase II Trial of Psilocybin-Assisted Therapy For Depression
12:33 PM EDT, 06/02/2022 (MT Newswires) -- Braxia Scientific Corp. (BRAX.CSE) a research company with clinics providing ketamine and psilocybin treatments for depression and related mental health diso
Braxia Scientific Presents Positive Preliminary Findings from Phase II Randomized, Multi-Dose Clinical Trial of Psilocybin-Assisted Therapy for Treatment Resistant Depression
TORONTO, June 2, 2022 /PRNewswire/ - Braxia Scientific Corp. ("Braxia Scientific", or the "Company"), (CSE: BRAX) (OTC: BRAXF) (FWB: 4960), a medical research company with clinics providing and adva
Proactive news headlines including Golden Arrow, Braxia Scientific, Irwin Naturals, PyroGenesis Canada and Pathway Health
New York , May 20, 2022 (GLOBE NEWSWIRE) -- Proactive, provider of real-time news and video interviews on growth companies listed in the US and Canada, has covered the following companies: Golden Arrow shifts focus to Chile and Argentina as Tie
Braxia Scientific Receives Health Canada Special Access Program Approval to Provide Psilocybin-Assisted Therapy for Depression in Ontario
Health Canada approval is for a patient with the indication of Major Depressive Disorder, in the absence of terminal medical illness or end of life distress Approval marks Braxia's first Special Acc
Braxia Scientific to Present at H.C. Wainwright Global Investment Conference, Miami from May 24-26, 2022
TORONTO, May 19, 2022 /PRNewswire/ - Braxia Scientific Corp. ("Braxia", or the "Company"), (CSE: BRAX) (OTC: BRAXF) (FWB: 4960), a medical research company with clinics providing innovative ketamine
Braxia Scientific CEO to Speak at American Psychiatric Association Annual Meeting on Treatment Resistant Depression and Ketamine Guidelines Published in American Journal of Psychiatry
TORONTO, May 18, 2022 /CNW/ - Braxia Scientific Corp. ("Braxia Scientific", or the "Company"), (CSE: BRAX) (OTC: BRAXF) (FWB: 4960) is pleased to announce that its CEO, Dr. Roger McIntyre has been inv
Certification and Hearing to Approve Proposed Settlement of Braxia Scientific Corp. Securities Class Action
TORONTO, May 9, 2022 /CNW/ - The parties to a proposed class action commenced against Braxia Scientific Corp. (formerly known as Champignon Brands Inc.), William Gareth Birdsall, Lucas Birdsall, Roger
Braxia Scientific CEO and CMO, Invited to Speak as Experts at the Ketamine and Related Compounds 2022 International Conference hosted by University of Oxford April 4-6
TORONTO, April 1, 2022 /PRNewswire/ - Braxia Scientific Corp. ("Braxia Scientific", or the "Company"), (CSE: BRAX) (OTC: BRAXF) (FWB: 4960), a medical research company with clinics providing innovat